SCHEMBL3548740

SCHEMBL3548740

CC(C)Nc1nccc(Oc2cccc(C=CC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.49
RAF1 P04049 4/20 0.46
RET P07949 2/20 0.46
CDK8 P49336 5/20 0.46
CCNC P24863 2/20 0.46
NAMPT P43490 1/20 0.45
BRAF P15056 3/20 0.44
MAPK14 Q16539 2/20 0.44
TNNI3K Q59H18 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MET P08581 2/20 0.42
PLK4 O00444 1/20 0.42
CIT O14578 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3548737 1.00 KDR (0.49) KDRRAF1RETCDK8CCNC
SCHEMBL3547742 0.88 KDR (0.49) KDRRAF1RETCDK8CCNC
SCHEMBL3547747 0.88 KDR (0.49) KDRRAF1RETCDK8CCNC
SCHEMBL3549408 0.86 KDR (0.46) KDRRAF1RETCDK8CCNC
SCHEMBL3549413 0.86 KDR (0.46) KDRRAF1RETCDK8CCNC
SCHEMBL3542320 0.85 KDR (0.47) KDRRAF1RETCDK8CCNC
SCHEMBL3542325 0.85 KDR (0.47) KDRRAF1RETCDK8CCNC
SCHEMBL3543464 0.85 KDR (0.45) KDRRAF1RETCDK8CCNC
SCHEMBL3543475 0.85 KDR (0.45) KDRRAF1RETCDK8CCNC
SCHEMBL3545327 0.84 KDR (0.49) KDRRAF1RETCDK8CCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652041-B2 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-01-26 US claimed
US-7652041-B2 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-01-26 US disclosed
US-20060160803-A1 Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160803-A1 Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity MAP3K21, HIPK4, MAP3K20 KDR 729/4885RAF1 693/4885RET 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.